Related Experiment Video
Updated: Oct 23, 2026
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells
M Fritzer1, T Szekeres, V Szüts
1Clinical Institute for Medical and Chemical Laboratory Diagnostics, University of Vienna, Medical School, Austria.
Abstract:
Cancer chemotherapy is often limited by the emergence of multidrug-resistant tumor cells. Multidrug resistance (MDR) can be caused by amplification of the MDR genes and overexpression of the P-glycoprotein, which is capable of lowering intracellular drug concentrations. A doxorubicin-transferrin conjugate has been synthesized and exerts its cytotoxic effects through a transmembrane mechanism. We have examined the cytotoxicity of this conjugate and compared it with doxorubicin in sensitive (KB-3-1) and in multidrug-resistant KB cell lines (KB-8-5, KB-C1, and KB-V1). In the clonogenic assay, doxorubicin exhibited IC50 concentrations of 0.03 and 0.12 microM in the sensitive (KB-3-1) and resistant (KB-8-5) cell lines, respectively, whereas, doxorubicin-transferrin conjugate was more effective with IC50 concentrations of 0.006 and 0.028 microM, respectively. In highly multidrug-resistant KB-C1 and KB-V1 cells, doxorubicin up to 1 microM did not cause any cytotoxic effects, while the doxorubicin-transferrin conjugate inhibited colony formation of these cells with IC50 levels of 0.2 and 0.025 microM, respectively. These results demonstrate that doxorubicin-transferrin is effective against multidrug-resistant tumor cells.
Insights
A novel doxorubicin-transferrin conjugate effectively combats multidrug-resistant (MDR) cancer cells. This conjugate shows superior efficacy compared to doxorubicin alone in resistant cell lines, offering a promising new avenue for cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Cancer chemotherapy faces limitations due to multidrug resistance (MDR) in tumor cells.
- MDR often results from MDR gene amplification and P-glycoprotein overexpression, reducing intracellular drug levels.
- Doxorubicin-transferrin conjugate offers a novel approach targeting transmembrane mechanisms for drug delivery.
Purpose of the Study:
- To synthesize and evaluate the cytotoxic efficacy of a doxorubicin-transferrin conjugate.
- To compare the conjugate's effectiveness against doxorubicin in both sensitive and multidrug-resistant cancer cell lines.
- To assess the conjugate's potential in overcoming P-glycoprotein-mediated drug resistance.
Main Methods:
- Synthesis of a doxorubicin-transferrin conjugate.
- Cytotoxicity evaluation using clonogenic assays.
- Comparison of IC50 values between the conjugate and doxorubicin in sensitive (KB-3-1) and resistant (KB-8-5, KB-C1, KB-V1) cell lines.
Main Results:
- Doxorubicin-transferrin conjugate demonstrated significantly lower IC50 values than doxorubicin in sensitive KB-3-1 cells (0.006 vs. 0.03 microM).
- The conjugate was effective against multidrug-resistant KB-8-5 cells (IC50 of 0.028 microM) where doxorubicin had reduced efficacy (IC50 of 0.12 microM).
- Doxorubicin-transferrin conjugate inhibited colony formation in highly resistant KB-C1 and KB-V1 cells (IC50s of 0.2 and 0.025 microM, respectively), while doxorubicin showed no effect.
Conclusions:
- Doxorubicin-transferrin conjugate exhibits enhanced efficacy against multidrug-resistant cancer cells.
- The conjugate effectively overcomes P-glycoprotein-mediated drug resistance.
- This conjugate represents a promising therapeutic strategy for overcoming chemotherapy resistance in cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...